FMP
Pacific Biosciences of California, Inc.
PACB
NASDAQ
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
1.23 USD
0.04 (3.25%)
Seeking Alpha
Aug 21, 2024
PacBio's Q2 2024 revenue dropped 24% YoY, primarily due to a sharp decline in instrument sales. Gross margin plummeted to 16%, reflecting increased costs and pricing pressures in a challenging market. Rising SG&A expenses, including employee separation costs, are pressuring PacBio's already weakened financials.
Zacks Investment Research
Aug 12, 2024
Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Research
Aug 8, 2024
PacBio's (PACB) Product revenues decline in the second quarter of 2024. However, Consumable and Service and other revenues increase year over year.
Zacks Investment Research
Aug 7, 2024
While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks Investment Research
Aug 7, 2024
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.26 per share a year ago.
Zacks Investment Research
Aug 7, 2024
PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.
Zacks Investment Research
Jul 30, 2024
The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.05, representing no change from its previous close.
Zacks Investment Research
Jul 24, 2024
Pacific Biosciences of California (PACB) concluded the recent trading session at $1.88, signifying a +1.62% move from its prior day's close.
Zacks Investment Research
Jul 24, 2024
PacBio (PACB) announces that Novogene is set to use PACB's Revio long-read sequencing system to expand the capabilities of its new lab in Munich, Germany.
GlobeNewsWire
Jul 15, 2024
MENLO PARK, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2024 financial results on Wednesday, August 7, 2024, at 4:30 pm Eastern Time.